Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ7176MR)

This product GTTS-WQ7176MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 0
Species	Chimeric
RefSeq	NM_001178098.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	930
UniProt ID	P15391

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7176MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ7128MR	IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	FE 999302
GTTS-WQ3556MR	IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	BAX069
GTTS-WQ11618MR	IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	MGD-006
GTTS-WQ11645MR	IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	MGD-013
GTTS-WQ11861MR	IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	MK-7684
GTTS-WQ10073MR	IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	L19TNF
GTTS-WQ11927MR	IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	MLN2045
GTTS-WQ13156MR	IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	PF-04383119

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST